Advanced visualization software developer Imaging Biometrics is touting results of an American College of Radiology Imaging Network (ACRIN) trial in patients with recurrent glioblastoma multiforme.
The study used dynamic susceptibility contrast MRI to measure relative cerebral blood volume (rCBV) as a prognostic marker for overall survival in patients with recurrent glioblastoma multiforme, an aggressive brain tumor. The results showed that declines in blood volume metrics on MR perfusion scans could predict overall survival in patients treated with Avastin.
Software from Imaging Biometrics was used to create rCBV images from MRI data for 21 patients from five different sites. Decreasing rCBV values when measured at either two or 16 weeks after the start of treatment predicted clear improvement and overall survival, according to the company.
